[{"data":1,"prerenderedAt":181},["ShallowReactive",2],{"drug-bromocriptine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":36,"contraindications":73,"warnings":83,"renal":84,"monitoring":85,"interactions":86,"review":87,"examples":90,"atc":102,"iran":104,"links":116,"populations":133,"usApproval":176},"bromocriptine",1,{"fa":7,"en":8},"بروموکریپتین","Bromocriptine","genitourinary-sex-hormones",{"fa":11,"en":12},"آگونیست دوپامین","Dopamine agonist",[14],{"name":15,"market":16},"Parlodel","US",[18,19,7,20],"parlodel","پارلودل","پرولاکتین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-2-5","tablet","oral","2.5 mg tablet (scored)",{"amount":28,"unit":29,"perUnit":24,"scored":30},2.5,"mg",true,[16],[33],{"source":34,"section":35},"fda-bromocriptine","3",[37,61],{"id":38,"disease":39,"label":40,"population":43,"type":47,"unit":29,"dose":48,"refs":50,"notes":53},"prl","hyperprolactinemia",{"fa":41,"en":42},"اختلال ناشی از هیپرپرولاکتینمی — ۱٫۲۵ تا ۲٫۵ mg یک بار با غذا","Hyperprolactinaemia-associated dysfunction — 1.25–2.5 mg once daily with food",{"minAge":44},{"value":45,"unit":46},18,"year","fixed",{"perDose":49,"perDoseMax":28,"dosesPerDay":5},1.25,[51],{"source":34,"section":52},"2.3",[54],{"text":55,"refs":58},{"fa":56,"en":57},"افزایش تا ۲٫۵ mg هر ۲ تا ۷ روز در صورت تحمل.","Increase by up to 2.5 mg every 2–7 days as tolerated.",[59],{"source":34,"section":60},"2",{"id":62,"disease":39,"label":63,"population":66,"type":47,"unit":29,"dose":69,"refs":70},"adenoma",{"fa":64,"en":65},"آدنوم مترشحه پرولاکتین — ۱۱ سال به بالا: ۱٫۲۵ تا ۲٫۵ mg یک بار","Prolactin-secreting adenoma — ≥11 y: 1.25–2.5 mg once daily",{"minAge":67},{"value":68,"unit":46},11,{"perDose":49,"perDoseMax":28,"dosesPerDay":5},[71],{"source":34,"section":72},"2.4",[74],{"id":75,"severity":76,"text":77,"refs":80},"ci","block",{"fa":78,"en":79},"سابقه بیماری دریچه قلب یا فیبروز پریکارد (و سایر موارد بخش ۴).","History of cardiac valvular disorder or pericardial fibrosis (and others in section 4).",[81],{"source":34,"section":82},"4",[],[],[],[],{"status":88,"reviewer":89,"date":89},"unverified",null,[91,97],{"regimen":38,"formulation":23,"input":92,"expect":95},{"ageYears":93,"weightKg":94},30,60,{"perDose":49,"tabletsPerDoseRounded":96,"upperPerDose":28},0.5,{"regimen":62,"formulation":23,"input":98,"expect":101},{"ageYears":99,"weightKg":100},15,55,{"perDose":49},[103],"G02CB01",{"status":105,"forms":106,"refs":111},"registered",[107],{"code":108,"en":109,"fa":110},"00179","BROMOCRIPTINE MESYLATE 2.5MG TAB","قرص بروموکریپتین مزیلات ۲٫۵ میلی‌گرم",[112],{"source":113,"section":114,"url":115},"darooyab-generic","G-2484\u002FBromocriptine","https:\u002F\u002Fwww.darooyab.ir\u002FG-2484\u002FBromocriptine",[117,121,125,128,131],{"kind":118,"url":119,"label":120},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=017962","NDA017962",{"kind":122,"url":123,"label":124},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=17f3a343-1782-4799-95ba-31dfe93be2cf","FDA Bromocriptine",{"kind":126,"url":127,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682079.html",{"kind":129,"url":130,"label":103},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G02CB01",{"kind":132,"url":115,"label":8},"darooyab",{"pregnancy":134,"lactation":143,"pediatric":152,"geriatric":160,"reproductive":168},{"level":135,"text":136,"quote":139,"refs":140},"avoid",{"fa":137,"en":138},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Postpartum Period: Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4)] .",[141],{"source":34,"section":142},"8.1",{"level":144,"text":145,"quote":148,"refs":149},"caution",{"fa":146,"en":147},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Avoid the use of bromocriptine mesylate during lactation in postpartum females.",[150],{"source":34,"section":151},"8.2",{"level":144,"text":153,"quote":156,"refs":157},{"fa":154,"en":155},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of bromocriptine mesylate have been established for the treatment of prolactin-secreting pituitary adenomas in pediatric patients 11 years of age and older.",[158],{"source":34,"section":159},"8.4",{"level":144,"text":161,"quote":164,"refs":165},{"fa":162,"en":163},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of bromocriptine mesylate did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.",[166],{"source":34,"section":167},"8.5",{"level":144,"text":169,"quote":172,"refs":173},{"fa":170,"en":171},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females : Patients not seeking pregnancy, or those harboring large adenomas, should be advised to use appropriate contraceptive measures during treatment with bromocriptine mesylate.",[174],{"source":34,"section":175},"8.3",{"kind":177,"refs":178,"id":120},"NDA",[179],{"source":34,"section":180},"SPL approval \u002F marketing category",1792191870757]